7 Top Gainers In Pharma Sector (ATHE, NSPR, NCNA…)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. Alterity Therapeutics Limited (ATHE)

Alterity, formerly known as Prana Biotech, is developing first-in-class therapies to treat neurodegenerative diseases.

Gained 33.85% to close Monday's (Apr.29) trading at $1.74.

News: No news

Clinical Trial & Near-term Catalyst:

The Company's lead drug candidate is PBT434 for the treatment of Parkinsonian disorders, and is in Phase 1 clinical program. This single- and multiple-ascending dose study, whose primary goal is to evaluate the safety and tolerability of PBT434, is expected to be completed in the second quarter of this year.

2. Enlivex Therapeutics Ltd. (ENLV)

Enlivex is a clinical-stage immunotherapy company.

Gained 17.05% to close Monday's trading at $10.30.

News: No news

Clinical Trials & Near-term Catalysts:

The Company's lead product candidate is ALLOCETRA.

-- A phase IIa clinical study of Allocetra for preventing post- bone marrow transplantation (BMT) complications has been completed. A continuation Phase II/III clinical trial with Allocetra further investigating its use for the prevention of complications post bone-marrow transplantation is expected to be initiated by early 2020. -- A Phase II trial for the prevention of post-BMT complications in steroid-refractory Graft versus host disease (GvHD) patients is expected to be initiated during 2020. -- A phase II trial of ALLOCETRA studying the prevention of cytokine storms and organ dysfunction associated with sepsis is expected to be initiated in Q4,2019. A phase Ib study in this indication is ongoing.

Recent events:

-- Enlivex Therapeutics Ltd is the result of the merger of publicly-traded Bioblast Pharma Ltd. with Enlivex Therapeutics Ltd., a VC-funded privately-held immunotherapy company. The merger agreement was executed on November 19, 2018. -- Enlivex Therapeutics was listed to the NASDAQ on March 26, 2019. -- On April 8, the Company announced the final closing of a private placement financing of ordinary shares priced at $12.25 per share, raising a total of approximately $8.4 million.

3. Alphatec Holdings Inc. (ATEC)

Alphatec is a medical device company that designs, develops and markets spinal fusion technology products and solutions for the treatment of spinal disorders.

Gained 15.87% to close Monday's trading at $3.65.

News: No news

Recent event:

On March 7, 2019, the Company reported fourth quarter and fiscal year 2018 financial results.

The net loss for the fourth quarter of 2018 was $10.63 million or $0.25 per share compared to a net profit of $9.05 million or $0.53 per share in the year-ago quarter. Total revenue in the fourth quarter of 2018 declined to $25.34 million from $26.28 million in the year-ago quarter.

Near-term Catalyst:

The Company is slated to release first quarter 2019 financial results on Thursday, May 9, 2019, after the market closes.

4. InspireMD Inc. (NSPR)

InspireMD is a commercial-stage medical device company marketing CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, and MGuard Prime EPS in patients with coronary artery disease.

Gained 14.80% to close Monday's trading at $4.81.

News: No news

Recent event:

On April 4, 2019, the Company offered to sell 486,957 shares of its common stock to the public at a price of $5.00 per share.

5. NuCana plc (NCNA)

NuCana is a clinical-stage biopharmaceutical company focused on improving survival outcomes for patients with cancer.

Gained 13.66% to close Monday's trading at $14.98.

News: No news

Anticipated Milestones in 2019:

-- Report interim data from a phase II study of Acelarin for patients with platinum-resistant ovarian cancer. -- Open a Phase III study of Acelarin combined with cisplatin as a first-line treatment for patients with advanced biliary tract cancer. -- Continue enrollment in the Phase III study (Acelarate) of Acelarin as a first-line treatment compared to gemcitabine for patients with metastatic pancreatic cancer. -- Report initial data from the ongoing phase Ib study of NUC-3373 in patients with advanced colorectal cancer in combination with other approved agents with which 5-FU is typically combined, including leucovorin, oxaliplatin, and irinotecan. -- Report interim data from the Phase I study of NUC-7738 in patients with advanced solid tumors.

6. Sesen Bio Inc. (SESN)

Sesen Bio, formerly Eleven Biotherapeutics Inc., is a late-stage clinical company developing next-generation antibody-drug conjugate therapies for the treatment of cancer.

Gained 12.73% to close Monday's trading at $1.24.

News: No news

Pipeline & Near-term Catalysts:

The Company's lead drug candidate is Vicinium, which is under a phase III trial in patients with high-grade non-muscle invasive bladder cancer, dubbed VISTA.

In January of this year, the Company reported positive preliminary efficacy data for the primary endpoint of its ongoing VISTA Trial - demonstrating clinically meaningful complete response rates in evaluable Carcinoma in situ patients at three, six, nine and 12 months of follow-up in the trial.

New, preliminary analyses from the VISTA trial further demonstrating the activity of Vicinium treatment in patients with high-risk non-muscle invasive bladder cancer were reported in March of this year.

Near-term Catalyst:

The Company is slated to report operating results for the first quarter ended March 31, 2019, and updated, preliminary primary and new secondary endpoint data from the Phase 3 VISTA trial on May 13, 2019.

7. Aravive Inc. (ARAV)

Aravive is a clinical stage biotechnology company developing therapies for solid tumors and hematologic malignancies.

Gained 11.40% to close Monday's trading at $6.45.

News: No news

Near-term Catalysts:

-- Interim safety, pharmacodynamic, and pharmacokinetic data for the Phase 1b portion of the Phase 1b/2 clinical trial of AVB-S6-500 in patients with platinum-resistant recurrent ovarian cancer are expected in the third quarter of 2019. -- A phase 1b clinical trial of AVB-S6-500 in patients with IgA nephropathy is expected to be initiated in the second half of 2019. -- The Phase 2 portion of the Phase 1b/2 clinical trial of AVB-S6-500 in patients with platinum-resistant recurrent ovarian cancer is expected to be initiated in the second half of 2019. -- A Phase 1b/2 clinical trial of AVB-S6-500 in patients with clear cell renal cell carcinoma is anticipated to be initiated in the second half of 2019.